EPS15

Across TCGA pan-cancer cohorts, EPS15 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EPS15 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EPS15 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EPS15 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and GBM are the cancer types where EPS15 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.867	0.604	<.001	45	view →
LUAD	DFS	Tertile	II,III,IV	0.836	0.187	.003	16	view →
GBM	OS	Tertile	All	0.417	0.628	.019	11	view →
HNSC	DFS	Median	IV	0.932	0.694	.026	2	view →
LSCC	DFS	Tertile	II,III,IV	0.865	1.000	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EPS15–PDAC (DFS)

Open the PDAC breakdown →